Rigor Reviewed

Rigor-Reviewed Manuscript

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.

Name: Αlpha¹ Rigor Record — Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
Item: Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
Rating: 39
Author: Αlpha¹

Rash BG, Ramdas KN, Agafonova N, Naioti E, McClain-Moss L, Zainul Z, Varnado B, Peterson K, Brown M, Leal T, Kopcho S, Carballosa R, Patel P, Brody M, Herskowitz B, Fuquay A, Rodriguez S, Jacobson AF, Leon R, Pfeffer M, Schwartzbard JB, Botbyl J, Oliva AA Jr, Hare JM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1★ (Critical), 2 critical, 2 high issues for “Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 15 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced6 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

Critical findings

• PERCENT: 41.7% does not match the reported count 5/13
• PERCENT: 8.3% does not match the reported count 1/11

This is a well-conducted and transparently reported phase 2a randomized controlled trial. The main methodological strengths are rigorous randomization/blinding, detailed reporting of demographics and ethics, and proportional conclusions. The primary weakness is the vague data/code availability statement, which limits reproducibility.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The statistics verification component checked only 3 tests (limited coverage) and found no demonstrable errors; the 2 'inconsistent' results were not listed and thus not treated as errors. The citation check found no retracted or unresolved references.

7 major claims checked against the paper's own evidence: 3 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT).

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on AD, anti-amyloid antibody limitations (lecanemab, aducanumab, donanemab), and the rationale for MSC therapy. It acknowledges the limitations of prior work (e.g., ARIAs with anti-amyloid drugs) and builds a logical rationale for laromestrocel. The hypothesis follows from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on AD pathology, limitations of current anti-amyloid therapies, and previous phase 1 data on laromestrocel.

Evidence

paraphrase[Introduction, paragraph 1]

“After many failures of monoclonal antibodies attempting to remove amyloid proteins from the brain, three drugs were approved by the US Food and Drug Administration (FDA) between 2021 and 2024.”

paraphrase[Introduction, paragraph 3]

“Cell-based therapy with mesenchymal stem cells (MSCs) is a particularly attractive treatment candidate as it encompasses provascular, anti-inflammatory, immunomodulatory and tissue repair mechanisms of action, with findings validated in a murine AD model.”

paraphrase[Introduction, paragraph 3]

“We have previously shown in a phase I study that laromestrocel (Lomecel-B) is safe in patients with mild AD and does not cause ARIAs, including in ApoE4 homozygous carriers.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior work on AD pathology, limitations of current anti-amyloid therapies, and previous phase 1 data on laromestrocel.

Evidence

paraphrase[Introduction, paragraph 1]

“After many failures of monoclonal antibodies attempting to remove amyloid proteins from the brain, three drugs were approved by the US Food and Drug Administration (FDA) between 2021 and 2024.”

paraphrase[Introduction, paragraph 3]

“We have previously shown in a phase I study that laromestrocel (Lomecel-B) is safe in patients with mild AD and does not cause ARIAs, including in ApoE4 homozygous carriers.”

Randomization method (block sizes of four, stratified by sex) and unit (patient) are reported. Blinding is described for all personnel. Power analysis is reported but acknowledges the study was not powered for the secondary endpoint. Inclusion/exclusion criteria are detailed. Outlier handling is not explicitly described but the analysis population (ITT/mITT) is defined. Controls (placebo) are appropriate. Independent replication is not applicable for a single trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with adequate randomization, blinding, and pre-specified endpoints, though the power analysis is underpowered for the secondary endpoint.

Evidence

direct quote[Methods, Study design and enrollment]

“Randomization was performed electronically using block sizes of four, equally allocated, with each site receiving separate blocks. Randomization was additionally stratified by sex.”